Conferences
Advertisement
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.
Dr. Avudaiappan compares radical prostatectomy with dose-escalated radiation with ADT for the treatment of prostate cancer.
At the AUA 2025 Annual Meeting, Dr. Guerrero-Ramos highlights the first results from Cohort 4 of SunRISe-1.
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
Drs. Chang, Joyce take a look at QUILT-3.032, including complete responses to N-803 plus BCG in BCG-unresponsive bladder CIS.
Dr. Daneshmand discusses some of the designs and results of ADVANCED-2, PIVOT-006, ABLE-22, and more.
Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade.
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.